HEALTHJun 7 · 23:35 UTCMARKETWATCHJaimy Lee

The Wegovy pill is still dominating the GLP-1 pill market

The Wegovy pill continues to be a leading choice for weight loss in the GLP-1 pill market in the U.S., maintaining its dominance despite the introduction of Foundayo, Eli Lilly’s competing GLP-1 pill.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

WegovytopicGLP-1 pill markettopicFoundayotopicEli Lillyorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 6 · 07:25 UTC
Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history
HEALTHMay 18 · 05:00 UTC
Novo Nordisk’s next obesity battlefront: Winning beyond America
BUSINESSMay 11 · 20:28 UTC
Hims Sales Miss on Rising Competition for Weight-Loss Drugs
HEALTHMay 31 · 15:56 UTC
What Ozempic is actually doing to obesity rates in the US
HEALTHMay 21 · 11:00 UTC
‘Wild West’ peptide craze surges beyond GLP-1s as FDA faces pressure to ease access
HEALTHMay 13 · 13:38 UTC
How do weight-loss drugs like Mounjaro and Wegovy work?